Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 81

1.

Fasting apolipoprotein B48 is a marker for peripheral arterial disease in type 2 diabetes.

Mancera-Romero J, Sánchez-Chaparro MA, Rioja J, Ariza MJ, Olivecrona G, González-Santos P, Valdivielso P.

Acta Diabetol. 2013 Jun;50(3):383-9. doi: 10.1007/s00592-012-0434-x. Epub 2012 Oct 9.

PMID:
23053881
2.

Postprandial apolipoprotein B48 is associated with asymptomatic peripheral arterial disease: a study in patients with type 2 diabetes and controls.

Valdivielso P, Puerta S, Rioja J, Alonso I, Ariza MJ, Sánchez-Chaparro MA, Palacios R, González-Santos P.

Clin Chim Acta. 2010 Mar;411(5-6):433-7. doi: 10.1016/j.cca.2009.12.022. Epub 2010 Jan 6.

PMID:
20059992
3.

Fasting apolipoprotein B48 is associated with asymptomatic peripheral arterial disease in type 2 diabetic subjects: a case-control study.

Lapice E, Cipriano P, Patti L, Romano G, Vaccaro O, Rivellese AA.

Atherosclerosis. 2012 Aug;223(2):504-6. doi: 10.1016/j.atherosclerosis.2012.05.038. Epub 2012 Jun 13.

PMID:
22762727
4.

Low lipoprotein lipase mass in preheparin serum of type 2 diabetes mellitus patients and its recovery with insulin therapy.

Miyashita Y, Shirai K, Itoh Y, Sasaki H, Totsuka M, Murano T, Watanabe H.

Diabetes Res Clin Pract. 2002 Jun;56(3):181-7.

PMID:
11947965
5.

The relationship of serum lipoprotein lipase mass with fasting serum apolipoprotein B-48 and remnant-like particle triglycerides in type 2 diabetic patients.

Kobayashi J, Nakajima K, Nohara A, Kawashiri M, Yagi K, Inazu A, Koizumi J, Yamagishi M, Mabuchi H.

Horm Metab Res. 2007 Aug;39(8):612-6.

PMID:
17712727
6.

Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

Valdivielso P, Rioja J, García-Arias C, Sánchez-Chaparro MA, González-Santos P.

Cardiovasc Diabetol. 2009 Jan 8;8:1. doi: 10.1186/1475-2840-8-1.

7.

The role of dietary cholesterol in the regulation of postprandial apolipoprotein B48 levels in diabetes.

Taggart C, Gibney J, Owens D, Collins P, Johnson A, Tomkin GH.

Diabet Med. 1997 Dec;14(12):1051-8.

PMID:
9455933
8.

Fasting APO B48 levels are associated with microalbuminuria in patients with type 2 diabetes.

Lapice E, Cipriano P, Patti L, Romano G, Vaccaro O, Rivellese AA.

Acta Diabetol. 2012 Oct;49(5):409-12. doi: 10.1007/s00592-012-0386-1. Epub 2012 Mar 20.

PMID:
22430605
9.

Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients.

Ohira M, Miyashita Y, Ebisuno M, Saiki A, Endo K, Koide N, Oyama T, Murano T, Watanabe H, Shirai K.

Diabetes Res Clin Pract. 2007 Oct;78(1):34-41. Epub 2007 Mar 19.

PMID:
17374417
10.

Preheparin lipoprotein lipase mass is a practical marker of insulin resistance in ambulatory type 2 diabetic patients treated with oral hypoglycemic agents.

Hanyu O, Miida T, Kosuge K, Ito T, Soda S, Hirayama S, Wardaningsih E, Fueki Y, Obayashi K, Aizawa Y.

Clin Chim Acta. 2007 Sep;384(1-2):118-23. Epub 2007 Jul 2.

PMID:
17651713
11.

Apo E genotype, diabetes, and peripheral arterial disease in older men: the Honolulu Asia-aging study.

Resnick HE, Rodriguez B, Havlik R, Ferrucci L, Foley D, Curb JD, Harris TB.

Genet Epidemiol. 2000 Jul;19(1):52-63.

PMID:
10861896
13.

Prevalence of peripheral arterial disease in type 2 diabetes mellitus and its correlation with coronary artery disease and its risk factors.

Agarwal AK, Singh M, Arya V, Garg U, Singh VP, Jain V.

J Assoc Physicians India. 2012 Jul;60:28-32.

PMID:
23405538
14.
15.

Associations of fetuin-A levels with vascular disease in type 2 diabetes patients with early diabetic nephropathy.

Roos M, Oikonomou D, von Eynatten M, Luppa PB, Heemann U, Lutz J, Baumann M, Nawroth PP, Bierhaus A, Humpert PM.

Cardiovasc Diabetol. 2010 Sep 7;9:48. doi: 10.1186/1475-2840-9-48.

16.

Association of serum apolipoprotein B48 level with the presence of carotid plaque in type 2 diabetes mellitus.

Tanimura K, Nakajima Y, Nagao M, Ishizaki A, Kano T, Harada T, Okajima F, Sudo M, Tamura H, Ishii S, Sugihara H, Yamashita S, Asai A, Oikawa S.

Diabetes Res Clin Pract. 2008 Sep;81(3):338-44. doi: 10.1016/j.diabres.2008.04.028. Epub 2008 Jul 16.

PMID:
18632179
17.

Cardiovascular risk factor management is poorer in diabetic patients with undiagnosed peripheral arterial disease than in those with known coronary heart disease or cerebrovascular disease. Results of a nationwide study in tertiary diabetes centres.

González-Clemente JM, Piniés JA, Calle-Pascual A, Saavedra A, Sánchez C, Bellido D, Martín-Folgueras T, Moraga I, Recasens A, Girbés J, Sánchez-Zamorano MA, Mauricio D; PADiD Study Group.

Diabet Med. 2008 Apr;25(4):427-34. doi: 10.1111/j.1464-5491.2008.02402.x. Epub 2008 Mar 13.

PMID:
18341592
18.

LOX-1 is a novel marker for peripheral artery disease in patients with type 2 diabetes.

Fukui M, Tanaka M, Senmaru T, Nakanishi M, Mukai J, Ohki M, Asano M, Yamazaki M, Hasegawa G, Nakamura N.

Metabolism. 2013 Jul;62(7):935-8. doi: 10.1016/j.metabol.2013.01.018. Epub 2013 Feb 19.

PMID:
23433938
19.

Increased serum apolipoprotein B48 concentration in patients with metabolic syndrome.

Kinoshita M, Ohnishi H, Maeda T, Yoshimura N, Takeoka Y, Yasuda D, Kusano J, Mashimo Y, Saito S, Shimamoto K, Teramoto T.

J Atheroscler Thromb. 2009 Aug;16(4):517-22. Epub 2009 Aug 27.

20.

An analysis of the relationship between ankle-brachial index and estimated glomerular filtration rate in type 2 diabetes.

Jin X, Ma JH, Shen Y, Luo Y, Su XF, Chen YY, Qi SK, Wu JD.

Angiology. 2013 Apr;64(3):237-41. doi: 10.1177/0003319712464515. Epub 2012 Nov 15.

PMID:
23162006

Supplemental Content

Support Center